Enanta Pharma Analyst Ratings
Baird Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $21
Enanta Pharmaceuticals: Promising RSV Developments and Strong Immunology Pipeline Justify Buy Rating
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $27
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
Buy Rating for Enanta Pharmaceuticals Amid Reduced Competition and Promising Drug Trials
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)
Leerink Partners Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating
Baird Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $26
Enanta Pharmaceuticals (ENTA) Gets a Hold From Leerink Partners
Enanta Pharma Analyst Ratings
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
Enanta Pharmaceuticals Gains Buy Rating on Strong Clinical Results for EDP-323
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution
Buy Rating Affirmed on Enanta Pharmaceuticals' Promising Drug Pipeline and Strategic Expansion Into Immunology
JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $10
Evercore ISI Sticks to Their Buy Rating for Enanta Pharmaceuticals (ENTA)